Every year, the ACR conducts a case-based image competition. Images are submitted for peer review. The winning images are displayed at ACR Convergence and winners receive other benefits, as well. This year, the overall winning images were submitted by Madhuri Challa, MD, of Hyderabad, Telangana, India. Presentation These are the representative clinical and radiological images…
A recently published study shows that inflammatory disease begins well before synovitis is seen on exam; a better understanding of what’s brewing before the storm could lead to the development of preventive therapies for RA.
With funding support from the CDC, in this ACR initiative, rheumatology fellows in training deliver lupus education sessions to medical personnel & rheumatologists connect with medical colleagues in underserved rural areas.
The recently released PREDMETH study results indicate that methotrexate can be considered a real alternative to prednisone for patients with pulmonary sarcoidosis.
VEXAS is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. Given the variability in disease presentation & the limited number of studies to date, an international multidisciplinary panel of VEXAS experts was convened to provide guidance to healthcare providers on the condition’s management. We spoke to experts on the panel about the resulting guidance document.
Long-term use of corticosteroids is associated with numerous adverse effects, particularly in children, but guidance is lacking on how to manage low-dose prednisone in clinically quiescent disease. In The Great Debate at ACR Convergence 2025—Corticosteroids in Pediatric SLE: Slay or Stay, two pediatric lupus experts took to the stage to explore this important topic.
In the ACR Convergence 2025 session, Great Debate: Ultrasound vs. Temporal Artery Biopsy in Giant Cell Arteritis, two vasculitis experts went head to head to determine the ideal first test in the diagnosis GCA: ultrasound or biopsy.
Research demonstrating the effectiveness of subcutaneous anifrolumab-fnia as an auto-injector in patients with active systemic lupus erythematosus is the basis of a recent decision in the EU to recommend the treatments approval for this patient population.
Explore the latest lupus nephritis advances in this supplement, covering CAR-T therapy, obinutuzumab data & new diagnostic tools.
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.